prostat
cancer
diagnos
million
men
everi
year
global
yet
current
diagnost
modal
inadequ
identif
signific
cancer
reliabl
earli
diagnost
biomark
necessari
improv
clinic
manag
prostat
cancer
patient
microrna
mirna
modul
import
cellular
processespathway
contribut
cancer
stabli
present
bodi
fluid
studi
profil
cancerassoci
mirna
plasma
collect
patient
afterdur
commenc
treatment
patient
agematch
prostat
cancer
patient
healthi
control
observ
elev
level
mirna
valid
independ
cohort
mirna
panel
abl
differenti
prostat
cancer
patient
control
auc
analysi
publish
mirna
transcriptom
data
clinic
sampl
demonstr
low
express
tumour
compar
adjac
nonmalign
tissu
overexpress
increas
prolifer
migrat
prostat
cancer
cell
suggest
role
mirna
prostat
cancer
pathogenesi
concept
support
pathway
analysi
predict
target
gene
summari
four
mirna
panel
includ
like
target
gene
key
role
prostat
cancer
pathogenesi
potenti
improv
earli
prostat
cancer
diagnosi
prostat
cancer
one
commonli
diagnos
cancer
men
worldwid
forecast
increas
incid
follow
year
base
current
trend
measur
level
prostat
specif
antigen
psa
also
known
human
serum
standard
first
line
test
indic
risk
prostat
cancer
wide
use
biomark
prostat
cancer
diagnosi
advent
psa
test
late
tool
prostat
cancer
diagnosi
enorm
benefit
prostat
cancer
patient
two
decad
howev
inadequaci
continu
exist
suitabl
use
diagnost
tool
earli
detect
prostat
cancer
due
lack
specif
high
rate
overdiagnosi
overtreat
associ
psa
test
therefor
urgent
clinic
need
better
diagnost
tool
prostat
cancer
although
prostat
biopsi
gold
standard
prostat
cancer
diagnost
tool
bound
sever
limit
prostat
biopsi
routin
perform
take
core
transrect
ultrasound
guidanc
increas
core
number
found
increas
cancer
detect
rate
fold
howev
major
drawback
lie
possibl
gener
fals
neg
sampl
often
taken
randomli
due
unknown
locat
tumour
patient
may
requir
repeat
biopsi
mri
guidanc
combin
ultrasound
better
sensit
recent
year
consider
research
led
develop
sever
molecular
genet
assay
provid
prospect
direct
develop
prostat
cancer
biomark
assay
utilis
bodi
fluidor
tissuebas
biomark
diagnosi
prognosi
risk
stratif
prostat
cancer
despit
recent
advanc
still
necessari
understand
role
test
overal
manag
prostat
cancer
patient
search
potenti
new
biomark
continu
express
select
plasma
mirna
discoveri
cohort
valid
find
screen
studi
quantit
candid
mirna
qrtpcr
individu
plasma
sampl
discoveri
cohort
n
consist
plasma
sampl
collect
agematch
patient
n
control
n
clinic
characterist
particip
summaris
supplementari
tabl
upregul
mirna
screen
studi
differenti
express
direct
howev
downregul
mirna
upregul
individu
patient
sampl
due
discrep
analys
candid
discard
remain
mirna
mirna
mean
foldregul
valu
significantli
alter
compar
control
determin
unpair
mannwhitney
u
test
follow
multipl
test
use
bonferroni
correct
p
fig
valid
plasma
valid
result
discoveri
cohort
assess
independ
set
patient
control
sampl
n
valid
cohort
compris
patient
control
patient
ie
valid
cohort
gleason
score
contrast
patient
discoveri
cohort
gleason
score
patient
ie
patient
ie
discoveri
cohort
gleason
score
patient
ie
valid
cohort
gleason
score
mean
age
patient
two
cohort
similar
ie
sd
year
sd
year
control
agematch
accordingli
supplementari
tabl
differenti
express
analysi
valid
cohort
confirm
level
significantli
alter
patient
compar
control
use
unpair
mannwhitney
u
test
follow
multipl
test
use
bonferroni
correct
p
fig
diagnost
mirna
signatur
prostat
cancer
given
associ
mirna
express
prostat
cancer
perform
univari
logist
regress
analysi
discoveri
n
valid
n
cohort
four
mirna
tabl
regress
coeffici
b
indic
estim
increas
odd
outcom
ie
prostat
cancer
increas
valu
exposur
ie
plasma
mirna
level
confid
interv
ci
use
measur
precis
regress
coeffici
determin
presenc
statist
signific
confirm
pvalu
found
significantli
associ
diseas
occurr
discoveri
cohort
except
reach
statist
signific
cohort
tabl
four
mirna
signific
valid
cohort
tabl
adjust
made
patient
control
sampl
vari
start
concentr
rna
use
offset
correct
binari
logist
regress
analysi
evalu
use
multivari
binari
logist
regress
roc
analys
diagnost
capac
individu
combin
discoveri
valid
cohort
well
cohort
combin
roc
analysi
mirna
panel
also
perform
discoveri
valid
combin
cohort
allow
comparison
auc
mirna
auc
four
mirna
togeth
measur
diagnost
accuraci
supplementari
figur
auc
individu
mirna
rang
respect
supplementari
figur
combin
predict
probabl
four
mirna
produc
area
curv
auc
p
ci
discoveri
cohort
fig
auc
p
ci
valid
cohort
fig
auc
p
ci
combin
cohort
fig
discrimin
prostat
figur
screen
plasma
mirna
marker
pool
patient
control
sampl
valid
discoveri
cohort
scatter
plot
cancerassoci
mirna
screen
cohort
pool
plasma
sampl
prostat
cancer
patient
healthi
control
screen
use
miscript
mirna
pcr
array
mirna
found
differenti
express
patient
control
group
shown
black
unchang
mirna
shown
grey
fold
regul
cutoff
select
analysi
b
scatter
plot
show
differenti
regul
mirna
reanalys
qrtpcr
patient
sampl
discoveri
cohort
n
mean
fold
regul
mirna
across
patient
control
sampl
taken
account
fold
regul
cutoff
exclud
analysi
select
mirna
shown
colour
c
rel
level
analys
qrtpcr
b
patient
vs
healthi
control
statist
signific
differ
assess
use
mannwhitney
u
test
p
valu
shown
bonferroni
correct
multipl
test
data
point
repres
plasma
sampl
horizont
middl
line
data
set
repres
mean
limit
vertic
line
repres
standard
deviat
rel
express
valid
cohort
n
statist
signific
differ
mirna
express
level
patient
control
group
assess
use
mannwhitney
u
test
p
valu
shown
bonferroni
correct
multipl
test
data
point
repres
plasma
sampl
horizont
middl
line
data
set
repres
mean
limit
vertic
line
repres
standard
deviat
scientif
report
cancer
patient
healthi
control
despit
differ
gleason
score
two
cohort
diagnost
accuraci
mirna
signatur
similar
discoveri
valid
combin
cohort
mirna
express
transcriptom
data
clinic
sampl
sinc
may
differ
express
mirna
circul
tumour
tissu
next
determin
whether
plasma
level
identifi
mirna
reflect
similar
chang
tumour
tissu
analysi
publish
mirna
transcriptom
data
clinic
sampl
tcga
dataset
demonstr
low
express
tumour
compar
adjac
nonmalign
tissu
p
wilcoxon
test
p
fig
figur
result
suggest
signific
p
increas
prolif
potenti
lncap
cell
upon
overexpress
use
mirna
mimic
fig
observ
substanti
increas
cell
confluenc
chang
cell
morpholog
mimic
treat
cell
compar
nontarget
neg
control
treat
cell
period
tabl
mirnet
predict
target
determin
experiment
part
larger
experi
microarray
rnaseq
qpcr
parclip
immunoprecipit
method
identifi
bind
site
cellular
rnabind
protein
rbp
micrornacontain
ribonucleoprotein
complex
mirnp
identifi
target
gene
support
experi
name
pubm
literatur
base
analysi
mirna
express
tcga
dataset
function
assay
target
use
input
ingenu
pathway
analysi
ipa
ipa
gener
canon
pathway
target
supplementari
tabl
prostat
cancer
signal
among
top
ten
canon
pathway
consist
deregul
target
gene
highlight
purpl
ie
kra
pten
p
fig
close
relat
henc
shown
group
analysi
molecular
function
gene
confirm
involv
cellular
process
cell
cycl
cell
morpholog
cell
growth
prolifer
cell
movement
supplementari
tabl
analysi
also
gener
list
upstream
regul
target
gene
supplementari
tabl
target
gene
six
overlap
gsea
prostat
cancer
found
second
import
pathway
among
top
kegg
pathway
supplementari
figur
furthermor
oncomin
data
analysi
gene
show
signific
upregul
p
figur
circul
mirna
bodi
fluid
may
serv
clinic
import
biomark
variou
malign
includ
prostat
cancer
present
studi
identifi
associ
elev
plasma
level
four
mirna
ie
prostat
cancer
patient
initi
analys
plasma
prostat
cancer
signal
among
top
ten
canon
pathway
consist
eight
deregul
target
gene
highlight
purpl
ie
kra
pten
close
relat
henc
shown
group
target
eg
kra
so
exist
complex
group
gene
p
valu
repres
p
analysi
mirnaom
agematch
prostat
cancer
patient
healthi
control
use
mirna
pcr
array
approach
select
sampl
pool
initi
screen
mirna
minimis
cost
reduc
analyt
run
time
compens
limit
amount
plasma
sampl
enabl
us
profil
larg
number
mirna
patient
control
sampl
cost
effect
way
employ
previou
studi
mani
biolog
experi
reli
pool
biolog
specimen
effici
method
also
statist
investig
previous
although
sampl
pool
advantag
optimum
approach
mitig
loss
inform
take
consider
biolog
variat
within
individu
sampl
may
lead
differ
observ
mirna
express
pool
individu
sampl
therefor
subsequ
qrtpcr
singl
sampl
discoveri
valid
cohort
perform
valid
result
mirna
deregul
direct
pool
individu
sampl
select
analysi
appli
stringent
cutoff
major
previous
conduct
studi
use
higher
c
cutoff
identifi
multipl
mirna
howev
appli
strict
cutoff
analysi
goal
determin
obviou
candid
rapid
identif
along
line
clinic
translat
identifi
mirna
signatur
gener
roc
curv
auc
valu
better
previous
report
auc
valu
psa
similarli
group
assess
diagnost
perform
plasma
serum
mirna
patient
localis
metastat
prostat
cancer
bph
healthi
control
instanc
specif
sensit
mirna
biomark
outperform
accuraci
psa
test
although
earli
detect
manag
prostat
cancer
complex
ongo
issu
insuffici
evid
support
benefit
populationbas
screen
prostat
cancer
australia
unit
state
use
psa
test
cancer
council
australia
us
prevent
servic
task
forc
recommend
psa
test
partli
due
overdiagnosi
overtreat
associ
psa
screen
healthi
men
uncommon
australia
thu
psa
valu
control
group
limit
abil
perform
mirna
vs
psa
comparison
studi
pertin
limit
studi
respect
patient
sampl
collect
primari
treatment
although
mirna
level
affect
treatment
regimen
patient
tri
mitig
effect
keep
time
sampl
collect
consist
discoveri
valid
cohort
use
appropri
statist
method
reli
stabil
mirna
bodi
fluid
studi
implic
prostat
cancer
diagnost
biomark
first
time
date
two
studi
investig
role
congenit
obstruct
nephropathi
exosom
biomark
may
provid
clue
explor
therapeut
potenti
prostat
cancer
identifi
recent
studi
kristensen
et
al
member
new
classifi
consist
predict
biochem
recurr
bcr
radic
prostatectomi
prostat
cancer
patient
studi
one
largest
mirna
express
profil
studi
tumour
tissu
sampl
patient
discoveri
cohort
patient
valid
cohort
howev
increas
level
plasma
previous
report
earli
diagnost
marker
prostat
cancer
member
five
mirna
signatur
correl
surviv
patient
hepatocellular
carcinoma
identifi
one
three
mirna
applic
diagnosi
patient
recent
studi
recent
studi
indic
import
colon
lung
liver
prostat
cancer
metaanalysi
six
mirna
dataset
reveal
upregul
mirna
one
recurr
compar
nonrecurr
prostat
sampl
suggest
predict
abil
along
mirna
best
knowledg
first
demonstr
plasma
candid
earli
diagnosi
prostat
cancer
final
previous
shown
substanti
decreas
higher
gleason
grade
prostat
cancer
tissu
low
express
correl
advanc
patholog
stage
express
pattern
line
find
tcga
dataset
lowli
express
tumour
compar
adjac
nonmalign
tissu
possibl
mechan
decreas
express
like
methyl
host
gene
promot
prevent
transcript
mirna
tumour
tissu
possibl
due
tumour
suppress
natur
anoth
mechan
could
releas
circul
enabl
tumour
growth
metastat
site
may
explain
result
obtain
function
assay
use
mimic
elev
level
plasma
propos
diagnost
biomark
cancer
lung
colorect
breast
cancer
find
suggest
potenti
detect
prostat
cancer
either
alon
combin
three
identifi
mirna
although
higher
level
mirna
may
indic
prostat
cancer
pathogenesi
mechan
action
difficult
determin
studi
report
circul
mirna
involv
cell
cell
commun
taken
recipi
cell
exert
function
effect
prolifer
invas
angiogenesi
exampl
tumour
exosom
mirna
shown
promot
metastasi
site
bodi
modul
stromal
cell
distant
organ
observ
signific
effect
overexpress
prolif
abil
prostat
cancer
cell
previous
suggest
zhu
et
al
contrast
found
overexpress
significantli
increas
prolifer
migrat
lncap
prostat
cancer
cell
suggest
regul
androgen
receptor
ar
may
account
observ
differ
contradictori
find
anoth
studi
theodor
et
al
low
express
correl
increas
prostat
cancer
metastasi
howev
may
provid
clue
metastat
role
mirna
distant
site
site
product
possibl
via
exosom
escap
mirna
known
play
role
metastasi
previous
report
exosom
mirna
also
believ
mirna
secret
select
process
therefor
scientif
report
circulatori
level
true
reflect
intracellular
level
contrari
mirna
releas
tumour
cell
argonaut
ago
bound
complex
dead
cell
apoptot
bodi
thu
indic
tumour
one
sourc
identif
mirnatarget
gene
pathway
understand
molecular
basi
prostat
cancer
pathogenesi
major
challeng
sever
risk
factor
numer
pathway
drive
cancer
four
mirna
target
select
analysi
due
signific
differenti
express
mirna
tcga
dataset
find
function
assay
depth
analysi
target
gener
target
gene
ipa
gsea
prostat
cancer
signal
pathway
six
common
target
two
analys
six
gene
found
import
modul
cellular
process
involv
cancer
progress
wellrecognis
oncogen
involv
direct
phosphoryl
retinoblastoma
rb
protein
promot
cell
cycl
transit
phase
overexpress
consider
portion
human
malign
breast
prostat
cancer
shown
mirna
target
breast
cancer
cell
primari
prostat
epitheli
cell
similarli
recent
studi
lynch
et
al
chakravarthi
et
al
demonstr
invers
correl
mirna
prostat
cancer
cell
line
clinic
prostatectomi
specimen
howev
observ
chang
mrna
express
lncap
cell
treatment
kra
wellestablish
oncogen
gtpase
protein
play
import
role
cell
divis
differenti
apoptosi
mirna
target
kra
recent
studi
induc
cell
apoptosi
vitro
exert
tumour
suppress
effect
vivo
xenograft
mice
model
colorect
cancer
suggest
import
mirnakra
axi
prostat
cancer
mirna
found
play
tumour
suppress
role
contrari
result
suggest
upregul
kra
mrna
level
treatment
lncap
cell
may
explain
increas
cell
prolifer
migrat
observ
function
studi
molecular
chaperon
promot
regul
specif
protein
involv
signal
transduct
cell
cycl
recent
studi
wilson
et
al
indic
import
histon
methyl
ar
bind
site
transcript
target
androgen
signal
prostat
cancer
progress
may
result
posit
regul
metastasi
shown
oncomin
data
analysi
wherea
express
possibl
remain
unchang
localis
cancer
due
stabl
complex
format
ar
observ
decreas
mrna
lncap
cell
mirna
treatment
suggest
possibl
target
turn
may
play
role
androgen
signal
pathway
guanin
nucleotid
exchang
factor
involv
ra
activ
stimul
seri
signal
cascad
crucial
malign
transform
recent
studi
all
et
al
demonstr
mirna
overexpress
kidney
cancer
cell
line
lead
reduc
level
endogen
therefor
target
so
factor
mirna
may
potenti
inactiv
ra
signal
howev
mani
factor
involv
signal
cascad
result
cancer
progress
pten
lipid
protein
phosphatas
capabl
regul
pathway
suppress
tumour
growth
mani
cancer
pten
express
function
regul
variou
mechan
includ
regul
mirna
coinactiv
report
increas
neuroendocrin
phenotyp
hallmark
prostat
cancer
progress
antiandrogen
therapi
target
pten
may
therefor
result
increas
cell
prolifer
migrat
observ
function
assay
howev
observ
chang
pten
mrna
level
treatment
contrari
previous
report
role
pten
also
found
pten
upregul
prostat
cancer
vs
normal
metastasi
vs
primari
prostat
cancer
differenti
express
pten
extract
particular
yu
prostat
dataset
oncomin
cancer
microarray
databas
dataset
select
dataset
largest
number
prostat
cancer
primarymetastasi
normal
sampl
comparison
target
gene
interest
although
pten
gener
consid
tumour
suppressor
may
act
tumour
promot
instanc
also
wide
known
addit
gene
express
genom
instabl
mutat
copi
number
variat
pten
gene
often
associ
prostat
cancer
estim
percent
primari
prostat
tumour
pten
gene
mutat
yu
prostat
dataset
oncomin
cancer
microarray
databas
take
account
data
analysi
result
pten
may
shown
upregul
addit
data
analysi
use
dataset
oncomin
take
pten
delet
copi
number
variat
account
reveal
trend
opposit
direct
evid
suggest
target
gene
discuss
far
play
vital
role
prostat
cancer
regul
mirna
may
crucial
prostat
cancer
pathogenesi
target
oncogen
tumour
suppressor
suggest
mirna
target
modul
depend
variou
aspect
genet
alter
transcript
posttranscript
regul
posttransl
modif
target
stabilis
indirect
regul
well
cell
type
moreov
valid
target
gene
function
studi
necessari
understand
mechanist
role
identifi
mirna
cancer
progress
conclus
major
strength
studi
one
largest
scale
studi
conduct
australian
men
determin
potenti
mirna
diagnost
marker
prostat
cancer
although
may
ideal
includ
similar
number
patient
control
sever
publish
studi
control
group
smaller
number
compar
patient
group
report
previous
addit
identifi
novel
plasma
mirna
panel
consist
four
mirna
previous
implic
earli
diagnosi
prostat
cancer
achiev
use
higher
normal
stringenc
identifi
reliabl
candid
uniqu
compar
mani
studi
beyond
scope
studi
compar
mirna
express
level
bph
patient
analys
sever
studi
discuss
review
articl
develop
field
biomark
research
ongo
stipul
emerg
mirna
current
test
specif
role
prostat
cancer
diagnosi
treatment
howev
critic
need
scientif
report
robust
reproduc
data
implement
biomark
clinic
practic
still
remain
undoubtedli
next
decad
substanti
number
biomark
avail
clinic
use
overal
manag
prostat
cancer
patient
blood
collect
retrospect
studi
examin
mirna
riskprotect
factor
relat
diagnost
outcom
prostat
cancer
patient
recruit
part
prostat
cancer
support
care
patient
outcom
project
proscan
randomis
control
trial
psycholog
intervent
newli
diagnos
prostat
cancer
patient
discoveri
cohort
n
valid
cohort
prostat
cancer
patient
n
recruit
part
australian
prostat
cancer
bioresourc
apcb
consist
patient
includ
men
recruit
via
collabor
urologist
men
qld
node
apcb
men
recruit
collabor
cancer
council
queensland
healthi
male
control
particip
discoveri
valid
cohort
n
recruit
elector
roll
part
queensland
men
health
studi
qldmen
crosssect
populationbas
studi
consist
men
includ
ageand
postal
codematch
control
complement
particip
proscan
apcb
studi
patient
control
number
select
depend
avail
sampl
particip
similar
clinic
characterist
well
refer
previou
studi
discuss
publish
review
articl
patient
group
cohort
divid
metastat
year
surviv
nonmetastat
patient
subdivis
ensur
categori
particip
ie
metastat
nonmetastat
healthi
cohort
consist
sampl
followup
data
year
avail
patient
includ
surviv
less
year
prostat
cancer
diagnosi
detail
age
psa
level
clinic
grade
gleason
score
patholog
state
tnm
stage
famili
histori
collect
document
clinic
characterist
diseas
patient
healthi
control
cohort
famili
histori
prostat
cancer
patient
control
cohort
famili
histori
prostat
cancer
blood
sampl
collect
within
month
diagnosi
within
month
treatment
includ
radic
prostatectomi
androgen
depriv
therapi
adt
brachytherapi
andor
radiat
therapi
patient
discoveri
cohort
n
similarli
valid
cohort
n
blood
collect
within
month
diagnosi
month
treatment
time
radic
prostatectomi
patient
collect
done
month
hormon
depriv
although
mirna
level
affect
treatment
regimen
patient
tri
mitig
effect
keep
time
sampl
collect
consist
discoveri
valid
cohort
use
appropri
statist
method
reli
stabil
mirna
bodi
fluid
blood
sampl
collect
ethylenediaminetetraacet
acid
edta
contain
tube
process
within
hour
collect
result
plasma
sampl
store
rna
extract
perform
transport
dri
ice
institut
health
biomed
innov
ihbi
rna
isol
clinic
sampl
obtain
patient
control
written
inform
consent
studi
perform
accord
institut
ethic
approvalapprov
number
proscan
apcb
qldmen
queensland
univers
technolog
qut
cancer
council
queensland
ccq
plasma
rna
isol
cdna
synthesi
prior
rna
isol
plasma
sampl
discoveri
valid
cohort
centrifug
min
g
plasma
sampl
screen
haemolysi
use
nanodrop
mirna
screen
fig
eight
random
plasma
pool
two
pool
per
group
gener
rna
extract
control
group
three
patient
group
discoveri
cohort
use
randomis
webbas
tool
http
wwwminiwebtoolcomrandompick
way
plasma
requir
per
pool
gener
divid
total
volum
requir
ie
number
sampl
per
pool
exampl
control
group
consist
healthi
male
divid
two
plasma
pool
control
control
contribut
plasma
control
contribut
plasma
similarli
three
patient
group
consist
sampl
divid
samplespool
respect
patient
per
group
contribut
plasma
plasma
plasma
therefor
total
rna
extract
pool
plasma
two
pool
per
patient
control
group
discoveri
cohort
elut
rnasefre
water
use
mirneasi
serumplasma
kit
qiagen
follow
manufactur
instruct
bacteri
ribosom
rna
roch
ad
sampl
increas
rna
recoveri
mirneasi
serumplasma
spikein
control
ie
qiagen
ad
sampl
intern
control
plasma
mirna
express
profil
normalis
qrtpcr
data
previous
describ
extract
rna
pool
plasma
sampl
revers
transcrib
use
miscript
ii
rt
kit
hispec
buffer
qiagen
accord
manufactur
instruct
fig
mirna
pcr
array
analysi
result
cdna
dilut
rnasefre
water
appli
miscript
mirna
pcr
array
qiagen
contain
forward
primer
detect
cancerassoci
mirna
duplic
intern
control
fig
qrtpcr
run
system
appli
biosystem
data
analys
use
geneglob
data
analysi
softwar
qiagen
spikein
control
use
program
calibr
data
set
mirna
pcr
array
data
normalis
global
mean
normalis
method
method
automat
calcul
global
c
mean
mirna
target
commonli
express
sampl
analys
initi
calibr
exogen
spikein
control
plasma
mirna
express
profil
individu
sampl
spikein
control
use
intern
control
normalis
qrtpcr
data
previous
scientif
report
describ
fold
regul
repres
fold
chang
valu
gener
mirna
express
profil
biolog
meaning
way
fold
chang
calcul
use
equat
fold
regul
fold
chang
valu
less
mean
mirna
downregul
transform
calcul
neg
invers
therefor
valu
remain
represent
chang
c
number
cycl
requir
fluoresc
signal
cross
set
threshold
invers
proport
mirna
level
valu
consid
neg
call
softwar
therefor
lower
limit
detect
c
avoid
fals
posit
final
valu
mirna
express
level
gener
biolog
meaning
way
fold
regul
ie
neg
invers
fold
chang
foldregul
cutoff
use
shortlist
deregul
mirna
one
challeng
mirna
profil
plasma
sampl
lack
establish
housekeep
gene
data
normalis
gener
mirna
profil
experi
use
small
noncod
rna
small
nuclear
nucleolar
rna
snrnassnorna
data
normalis
howev
may
serv
ideal
refer
gene
snorna
snrna
share
properti
mirna
term
express
transcript
process
therefor
normalis
data
perform
use
exogen
intern
control
global
mean
normalis
approach
qrtpcr
valid
rna
extract
individu
plasma
sampl
n
cdna
synthesi
perform
describ
previous
result
cdna
dilut
rnasefre
water
qrtpcr
shortlist
matur
mirna
perform
use
miscript
primer
assay
forward
primer
qiagen
univers
primer
revers
primer
qiagen
quantitect
sybr
green
pcr
master
mix
qiagen
cdna
input
reaction
triplic
mirna
revers
transcript
control
mirtc
primer
assay
qiagen
use
intern
control
determin
revers
transcript
effici
sampl
qrtpcr
data
analys
use
extern
spikedin
qiagen
housekeep
figur
studi
design
discoveri
valid
cohort
studi
profil
flow
diagram
summaris
methodolog
statist
approach
use
identifi
diagnost
mirna
follow
silico
target
identif
pathway
analysi
tcga
data
express
analysi
function
assay
scientif
report
gene
foldregul
cutoff
use
identifi
deregul
mirna
result
obtain
discoveri
cohort
valid
valid
cohort
n
use
method
describ
statist
analys
unpair
mannwhitney
u
test
perform
identifi
differ
mirna
express
level
patient
healthi
control
cohort
pvalu
adjust
multipl
test
use
bonferroni
correct
univari
logist
regress
perform
determin
abil
individu
mirna
predict
diseas
occurr
prostat
cancer
patient
rna
concentr
set
offset
variabl
account
differ
start
amount
rna
capac
combin
mirna
distinguish
patient
healthi
control
evalu
roc
curv
analysi
discoveri
n
valid
n
combin
n
cohort
increas
predict
power
analysi
roc
analysi
mirna
panel
binari
logist
regress
analysi
perform
four
mirna
time
enabl
calcul
predict
probabl
mirna
combin
use
gener
auc
valu
mirna
panel
auc
effect
combin
measur
sensit
specif
describ
inher
valid
diagnost
test
roc
curv
correspond
progress
greater
discrimin
capac
diagnost
test
locat
closer
upper
lefthand
corner
away
diagon
refer
line
pvalu
consid
signific
analys
statist
analys
done
use
graphpad
prism
spss
rstudio
consult
qualifi
statistician
queensland
facil
advanc
bioinformat
qfab
uq
research
method
group
rmg
qut
overal
summari
methodolog
present
fig
tcga
data
cell
line
express
analysi
prostat
express
shortlist
mirna
assess
publicli
avail
cohort
compris
tumour
nonmalign
prostat
tissu
cancer
genom
atla
tcga
express
significantli
deregul
mirna
prostat
tumour
tissu
evalu
panel
prostat
cancer
cell
line
qrtpcr
rna
extract
cell
lysat
use
mirneasi
micro
kit
qiagen
accord
manufactur
instruct
follow
cdna
synthesi
use
miscript
ii
rt
kit
hispec
buffer
qiagen
qrtpcr
use
miscript
primer
assay
qiagen
quantitect
sybr
green
pcr
master
mix
qiagen
perform
describ
previous
cell
prolifer
migrat
assay
cell
prolifer
assay
lncap
cell
plate
per
well
well
plate
allow
grow
hour
transient
transfect
mirna
complex
describ
cell
migrat
assay
imagelock
plate
essen
bioscienc
coat
polylornithin
sigma
overnight
cellswel
plate
next
day
allow
form
confluent
monolay
hour
cell
treat
aphidicolin
sigma
antimitot
reagent
hour
minimis
effect
cell
prolifer
migrat
wound
creat
use
woundmak
essen
bioscienc
growth
media
aspir
remov
cell
debri
cell
treat
mirna
complex
per
well
half
hour
replenish
rpmi
contain
fb
percentag
confluenc
prolifer
rel
wound
densiti
migrat
measur
everi
hour
hour
use
autom
incucyt
live
cell
imag
system
essen
bioscienc
follow
manufactur
protocol
treatment
perform
six
replic
three
independ
experi
data
analysi
perform
use
incucyt
softwar
pathway
analysi
silico
networkbas
visual
analysi
perform
use
mirnet
webbas
platform
identifi
target
gene
pathway
potenti
alter
mirna
signatur
forward
map
allow
user
map
mirna
target
perform
upload
list
mirna
id
interest
data
process
result
present
interact
tabl
row
correspond
one
mirna
target
tabl
also
provid
hyperlink
correspond
databas
mirnatarget
interact
deriv
togeth
refer
pubm
literatur
network
visualis
perform
function
annot
base
kyoto
encyclopedia
gene
genom
kegg
pathway
databas
hypergeometr
algorithm
use
enrich
analysi
input
data
gener
list
mirna
target
gene
use
input
depth
analysi
use
ipa
qiagen
determin
top
canon
pathway
upstream
regul
molecular
cellular
function
mirna
target
gene
associ
deregul
target
gene
diseas
phenotyp
also
confirm
use
gene
set
enrich
analysi
gsea
comput
method
differenti
express
target
gene
normal
n
vs
prostat
carcinoma
n
tissu
determin
use
oncomin
cancer
microarray
databas
integr
datamin
platform
pvalu
consid
signific
analys
valid
silico
target
gene
lncap
cellswel
plate
well
plate
treatment
neg
control
mimic
hour
describ
collect
cell
lysat
norgen
follow
rna
extract
norgen
cdna
synthesi
life
technolog
qrtpcr
life
technolog
determin
rel
fold
express
target
gene
use
targetspecif
primer
sigma
data
normalis
housekeep
gene
normalis
rel
nontarget
neg
control
determin
rel
fold
express
differ
target
gene
express
neg
control
treat
cell
assess
use
unpair
test
n
p
p
p
p
data
avail
statement
dataset
gener
andor
analys
current
studi
avail
correspond
author
reason
request
